Medifast, Inc. (MED) has been strategically positioning itself to thrive in the rapidly evolving weight loss market, particularly as the adoption of GLP-1 medications reshapes industry dynamics. With projections indicating that up to 20 million people in the United States could be using GLP-1 medications by 2030, Medifast is seizing this transformative opportunity by aligning its efforts with the market's evolving needs. Medifast's Expansion Initiatives Medifast is actively enhancing its product offerings, ...

Medifast, Inc. (MED) , a leading weight management and healthy living products company, has faced a tough period, with its stock declining significantly by 24.7% over the past three months. This decline is notably steeper compared with the industry's decline of 5.4% and the Zacks Food - Miscellaneous sector's marginal decline of 1% in the same timeframe. The current stock price is down 79% from its 52-week high of $92.13, highlighting the severity of the downturn. Medifast's stock is trading below its 50-da ...

Medifast, Inc. (MED) reported second-quarter 2024 results, with the bottom and top lines declining year over year. However, both earnings and net revenues beat the Zacks Consensus Estimate. Medifast is strategically adjusting its operations to meet the changing demands of the weight loss industry. This involves expanding its customer outreach through enhanced marketing efforts and entering the medically supported weight loss domain in partnership with LifeMD. These steps are designed to increase its market ...

Medifast, Inc. (NYSE:MED) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson David Larsen - BTIG Operator And welcome to the Medifast Second Quarter 2024 Earnings Conference Call. At this time, all participants are on a listen-only mode. A brief question-a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________. Commission File Number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3714405 | --- | ...

Medifast Announces Second Quarter 2024 Financial Results August 5, 2024 BALTIMORE – (BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 • Revenue of $168.6 million, with revenue per active earning Coach of $4,972 • Independent active earning OPTAVIA Coaches of 33,900 • Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 ...

Medifast, Inc. (MED) is likely to register a top and bottom-line decline when it reports second-quarter 2024 earnings on Aug 5. The Zacks Consensus Estimate for revenues is pegged at $160.4 million, which indicates a 45.8% slump from the year-ago period. The consensus mark for earnings has remained unchanged in the past 30 days at 36 cents per share, which suggests a substantial decline of 87% from the year-ago quarter's figure. MED has a trailing four-quarter earnings surprise of 48.7%, on average. Factors ...

The Zacks Consensus Estimate for 2024 earnings per share has declined from $2.80 to 94 cents in the past 30 days. Additionally, this Zacks Rank #5 (Strong Sell) stock has slumped 44.1% in the past three months compared with the industry's decline of 4.3%. Medifast has been encountering difficulties in attracting customers, primarily because of a range of macroeconomic elements, such as the increasing popularity of GLP-1 medications, the rapidly changing economy and shifts in social media algorithms. Undoubt ...

Medifast, Inc. (MED) delivered first-quarter 2024 results, with the top and bottom lines declining year over year. While the bottom line missed the Zacks Consensus Estimate, the top line exceeded the same.Medifast is strategically adjusting its operations to meet the changing demands of the weight-loss industry. This involves expanding its customer outreach through enhanced marketing efforts and entering the medically-supported weight-loss domain in partnership with LifeMD.These steps are designed to increa ...

Medifast (NYSE:MED) stock is falling on Tuesday after the weight loss company released its earnings report for the first quarter of 2024.The bad news for MED stock comes from its adjusted earnings per share of 66 cents. That’s well below Wall Street’s estimate of 80 cents for the quarter. It’s also much worse than the $3.67 per share reported in the same period of the year prior.Medifast also reported revenue of $174.74 million during Q1. That’s better than the $173.45 million analysts were expecting. Howev ...